{"id":104424,"date":"2020-11-23T11:11:19","date_gmt":"2020-11-23T11:11:19","guid":{"rendered":"https:\/\/www.edristi.in\/?p=104424"},"modified":"2020-11-23T11:12:03","modified_gmt":"2020-11-23T11:12:03","slug":"pfizer-and-biontech-covid-19-vaccine","status":"publish","type":"post","link":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/pfizer-and-biontech-covid-19-vaccine\/","title":{"rendered":"Pfizer and BioNTech COVID-19 Vaccine"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Question: On 20 November 2020; Pfizer Inc. and BioNTech announced they are going to submit a request for Emergency Use of their COVID-19 vaccine. To which of the following country BioNTech belongs?<br><\/strong>a) Japan<br>b) Germany<br>c) India<br>d) USA<br><strong>Answer: (b)<br>Related Facts:-<\/strong><\/p>\n\n\n\n<ul class=\"wp-block-list\"><li>On 20 November2020; Pfizer Inc. and BioNTech announced they are going to submit a request for Emergency Use of their COVID-19 vaccine.<\/li><li>These companies are applying for it to US Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of their mRNA vaccine candidate, BNT162b2.<\/li><li>This authorization will potentially enable use of the vaccine in high-risk populations in the U.S. by the middle to end of December 2020.<\/li><li>The submission is based on a vaccine efficacy rate of 95% (p&lt;0.0001) demonstrated in the companies\u2019 Phase 3 clinical study.<\/li><li>Phase 3 clinical studies were done in participants without prior SARS-CoV-2 infection (first primary objective) and also in participants with and without prior SARS-CoV-2 infection (second primary objective).<\/li><li>In each case it has been measured from 7 days after the second dose.<\/li><li>The first primary objective analysis was based on 170 confirmed cases of COVID-19.<\/li><li>This submission also is supported by solicited safety data from a randomized subset of approximately 8,000 participants \u226518 years of age.<\/li><li>It has also taken unsolicited safety data from approximately 38,000 trial participants who have been followed for a median of two months following the second dose of the vaccine candidate.<\/li><li>The submission also includes solicited safety data on approximately 100 children 12-15 years of age.<\/li><li>Approximately 42% of global participants and 30% of U.S. participants in the Phase 3 study have racially and ethnically diverse backgrounds.<\/li><li>It should be known that 41% of global and 45% of U.S. participants are 56-85 years of age.<\/li><li>Most importantly till date, the Data Monitoring Committee (DMC) for the study has not reported any serious safety concerns related to the vaccine.<\/li><li>Companies said that filing in the U.S. represents a critical milestone in our journey to deliver a COVID-19 vaccine to the world.<\/li><li>Companies informed, they now have a more complete picture of both the efficacy and safety profile about this vaccine.<\/li><\/ul>\n\n\n\n<p class=\"has-text-align-right wp-block-paragraph\"><strong>By &#8211; Rajesh Tripathi<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Link:-<\/strong><br><a href=\"https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-submit-emergency-use-authorization\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-submit-emergency-use-authorization<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Question: On 20 November 2020; Pfizer Inc. and BioNTech announced they are going to submit a request for Emergency Use of their COVID-19 vaccine. To which of the following country BioNTech belongs?a) Japanb) Germanyc) Indiad) USAAnswer: (b)Related Facts:- On 20 November2020; Pfizer Inc. and BioNTech announced they are going to submit a request for Emergency [&hellip;]<\/p>\n","protected":false},"author":9,"featured_media":104425,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1123],"tags":[3067],"class_list":["post-104424","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-snes","tag-scientific"],"_links":{"self":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/104424","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/users\/9"}],"replies":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/comments?post=104424"}],"version-history":[{"count":1,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/104424\/revisions"}],"predecessor-version":[{"id":104426,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/posts\/104424\/revisions\/104426"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media\/104425"}],"wp:attachment":[{"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/media?parent=104424"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/categories?post=104424"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.edristi.in\/hi\/%e0%a4%b9%e0%a5%8b%e0%a4%ae\/wp-json\/wp\/v2\/tags?post=104424"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}